JP2021526365A5 - - Google Patents
Info
- Publication number
- JP2021526365A5 JP2021526365A5 JP2020564560A JP2020564560A JP2021526365A5 JP 2021526365 A5 JP2021526365 A5 JP 2021526365A5 JP 2020564560 A JP2020564560 A JP 2020564560A JP 2020564560 A JP2020564560 A JP 2020564560A JP 2021526365 A5 JP2021526365 A5 JP 2021526365A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- hla
- tumor
- cell composition
- subpopulations
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862673745P | 2018-05-18 | 2018-05-18 | |
| US62/673,745 | 2018-05-18 | ||
| PCT/US2019/033182 WO2019222760A1 (en) | 2018-05-18 | 2019-05-20 | Improved targeted t-cell therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021526365A JP2021526365A (ja) | 2021-10-07 |
| JP2021526365A5 true JP2021526365A5 (https=) | 2022-05-30 |
Family
ID=68541068
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020564560A Pending JP2021526365A (ja) | 2018-05-18 | 2019-05-20 | 改善された標的化ｔ細胞療法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230002730A1 (https=) |
| EP (1) | EP3796923A4 (https=) |
| JP (1) | JP2021526365A (https=) |
| CN (1) | CN112512538A (https=) |
| CA (1) | CA3100775A1 (https=) |
| WO (1) | WO2019222760A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12188004B2 (en) | 2012-05-08 | 2025-01-07 | The Johns Hopkins University | Cancer immunotherapy using transfusions of allogeneic, tumor-specific CD4+ T cells |
| AU2013260132B2 (en) | 2012-05-08 | 2017-12-14 | The Johns Hopkins University | Methods and compositions for infusion of transiently engrafting, selected populations of allogeneic lymphocytes to treat cancer |
| US20180072990A1 (en) * | 2015-03-20 | 2018-03-15 | Children's National Medical Center | Generating virus or other antigen-specific t cells from a naïve t cell population |
| GB201604458D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against cancers |
| DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
| CN110651189B (zh) | 2017-03-03 | 2024-10-25 | 特雷斯生物有限公司 | 肽疫苗 |
| MX2019015879A (es) * | 2017-07-07 | 2020-02-07 | Immatics Biotechnologies Gmbh | Nuevos peptidos y nuevas combinacones de peptidos para el uso en la inmunoterapia contra el cancer de pulmon, incluyendo el nsclc, el sclc y otros canceres. |
| JP7642530B2 (ja) | 2018-09-04 | 2025-03-10 | トレオス バイオ リミテッド | ペプチドワクチン |
| WO2020146434A2 (en) * | 2019-01-07 | 2020-07-16 | Children's National Medical Center | Ex vivo activated t-lymphocytic compositions and methods of using the same |
| US20220160767A1 (en) * | 2019-05-31 | 2022-05-26 | Children's National Medical Center | Cytokine cocktails for selective expansion of t cell subsets |
| JP7811013B2 (ja) * | 2020-02-10 | 2026-02-04 | ザ・ジョンズ・ホプキンス・ユニバーシティ | 同種異系、腫瘍特異的なｃｄ４＋ ｔ細胞の注射移植を用いたがん免疫療法 |
| CN114524870A (zh) * | 2020-11-23 | 2022-05-24 | 香雪生命科学技术（广东）有限公司 | 源自于ssx2抗原的短肽 |
| US20220257651A1 (en) * | 2020-12-23 | 2022-08-18 | Mana Therapeutics | Methods and delivery of allogeneic cell products |
| EP4320435A1 (en) * | 2021-04-09 | 2024-02-14 | Achilles Therapeutics UK Limited | Batch release assay for pharmaceutical products relating to t cell therapies |
| CN115677846A (zh) * | 2021-07-27 | 2023-02-03 | 香雪生命科学技术（广东）有限公司 | 针对抗原ssx2的高亲和力t细胞受体 |
| CN115819555A (zh) * | 2021-09-17 | 2023-03-21 | 香雪生命科学技术（广东）有限公司 | 一种识别ssx2的高亲和力tcr |
| CN114478712B (zh) * | 2022-03-29 | 2022-09-23 | 深圳吉诺因生物科技有限公司 | Hpv抗原表位及其鉴定方法、应用 |
| CN117946246B (zh) * | 2023-02-23 | 2024-08-06 | 暨南大学 | 一种识别mage-a3抗原短肽的t细胞受体及其应用 |
| CN117402218B (zh) * | 2023-12-15 | 2024-02-20 | 上海惠盾因泰生物科技有限公司 | 一种Survivin阳性肿瘤的个体化树突状细胞疫苗及其制备方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2243235C (en) * | 1996-01-17 | 2010-08-10 | Imperial College Innovations Limited | Immunotherapy using cytotoxic t lymphocytes (ctl) |
| ES2367643T3 (es) * | 2005-04-26 | 2011-11-07 | Immatics Biotechnologies Gmbh | Identificador de un epítopo de linfocitos t presentado por el antígeno hla-a2 y derivado de la proteína del receptor de laminina inmadura del antígeno oncofetal y usos de este. |
| CN102625832A (zh) * | 2009-08-24 | 2012-08-01 | 贝勒医学院 | 产生对多种肿瘤抗原或多种病毒特异的ctl细胞系 |
| EP3066130B1 (en) * | 2013-11-07 | 2019-05-15 | Memorial Sloan-Kettering Cancer Center | Anti-wt1/hla bi-specific antibody |
| EP3212774A4 (en) * | 2014-10-31 | 2018-04-11 | Baylor College of Medicine | Survivin specific t-cell receptor targeting tumor but not t cells |
| WO2016145578A1 (en) * | 2015-03-13 | 2016-09-22 | Syz Cell Therapy Co. | Methods of cancer treatment using activated t cells |
| US20180072990A1 (en) * | 2015-03-20 | 2018-03-15 | Children's National Medical Center | Generating virus or other antigen-specific t cells from a naïve t cell population |
| US11299708B2 (en) * | 2016-05-12 | 2022-04-12 | Adicet Bio, Inc. | Methods for selective expansion of γδ T-cell populations and compositions thereof |
| US20200182884A1 (en) * | 2016-06-27 | 2020-06-11 | Juno Therapeutics, Inc. | Method of identifying peptide epitopes, molecules that bind such epitopes and related uses |
-
2019
- 2019-05-20 JP JP2020564560A patent/JP2021526365A/ja active Pending
- 2019-05-20 CA CA3100775A patent/CA3100775A1/en active Pending
- 2019-05-20 CN CN201980046752.2A patent/CN112512538A/zh active Pending
- 2019-05-20 US US17/056,714 patent/US20230002730A1/en active Pending
- 2019-05-20 WO PCT/US2019/033182 patent/WO2019222760A1/en not_active Ceased
- 2019-05-20 EP EP19803263.3A patent/EP3796923A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021526365A5 (https=) | ||
| Anderson III et al. | Genetic models of human and mouse dendritic cell development and function | |
| Díaz-Montero et al. | The immunology of renal cell carcinoma | |
| Gagelmann et al. | Tandem autologous stem cell transplantation improves outcomes in newly diagnosed multiple myeloma with extramedullary disease and high-risk cytogenetics: a study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation | |
| JP2022543702A5 (https=) | ||
| Clavijo et al. | Resistance to CTLA-4 checkpoint inhibition reversed through selective elimination of granulocytic myeloid cells | |
| Wirsdörfer et al. | Thorax irradiation triggers a local and systemic accumulation of immunosuppressive CD4+ FoxP3+ regulatory T cells | |
| Sandoval-Borrego et al. | Overexpression of CD158 and NKG2A inhibitory receptors and underexpression of NKG2D and NKp46 activating receptors on NK cells in acute myeloid leukemia | |
| Papa et al. | Acute leukaemia in patients treated for Hodgkin's disease | |
| Auge et al. | Microenvironment remodeling and subsequent clinical implications in diffuse large B-cell histologic variant of Richter syndrome | |
| Giebel et al. | Current status and achievements of Polish haemato-oncology | |
| Apostolova et al. | Phase II trial of hypomethylating agent combined with nivolumab for acute myeloid leukaemia relapse after allogeneic haematopoietic cell transplantation—Immune signature correlates with response | |
| Musto et al. | Primary plasma cell leukemia in the era of new drugs: has something changed? | |
| Krijgsman et al. | The effects of tumor resection and adjuvant therapy on the peripheral blood immune cell profile in patients with colon carcinoma | |
| Zhu et al. | Decitabine before low-dose cytarabine-based chemotherapy combined with human leukocyte antigen–mismatched stem cell microtransplantation improved outcomes in elderly patients with newly diagnosed acute myeloid leukemia | |
| Yu et al. | Comparison of efficacy between HLA6/6-and HLA3/6-matched haploidentical hematopoietic stem cell transplant in T-cell-replete transplants between parents and children | |
| Suemori et al. | Identification of an epitope derived from CML66, a novel tumor‐associated antigen expressed broadly in human leukemia, recognized by human leukocyte antigen‐A* 2402‐restricted cytotoxic T lymphocytes | |
| Heß | Checkpoint inhibition in non-Hodgkin's lymphoma | |
| García-Jiménez et al. | A high-resolution, unbiased analysis of the cellular immune response to Epstein-Barr virus | |
| Goldberg et al. | The role of hematopoietic stem cell transplantation in peripheral T-cell lymphomas | |
| Zhang et al. | Ki-67 can predict the response to the gemcitabine, oxaliplatin and L-asparaginase regimen (GELOX) and prognosis in patients with nasal natural killer/T-cell lymphoma | |
| Bhamidipati et al. | Epstein-Barr Virus–Induced CD30-Positive Diffuse Large B-Cell Lymphoma in a Patient With Mixed-Phenotypic Leukemia Treated With Clofarabine | |
| Lad et al. | Chronic lymphocytic leukemia: inception to cure: are we there? | |
| Intergroup | AbstractsDokumentation und Evaluation der Weiterbildung | |
| Forsthuber et al. | 442 Deciphering fibroblast heterogeneity in human skin cancer |